A Review of the Efficacy and Safety of Canagliflozin in Elderly Patients with Type 2 Diabetes

Elmore, Lindsey K.; Baggett, Sara; Kyle, Jeffrey A.; Skelley, Jessica W.

doi:10.4140/tcp.n.2014.335

Cited by 31 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28] This showed that our findings were reasonable. Furthermore, the results from a review of the efficacy and safety of canagliflozin in elderly patients indicated that elderly patients with T2DM have lesser HbA1c reduction compared with that in younger patients, [18] which needs further researches.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of canagliflozin in patients with type 2 diabetes

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, 2 of them included both phase II and phase III clinical trials with different treatment durations. [17,18] Among their pooled articles, the treatment durations were vastly different (12, 24, 26, and 52 weeks). Yang et al [17] evaluated the efficacy and safety of canagliflozin 300 mg versus those of the control groups.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of canagliflozin in patients with type 2 diabetes

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Common adverse events include urinary tract infections, genital mycotic infections, hypotension/volume depletion, lipid alterations, hypoglycemia, and renal insufficiency 156,161–165. The efficacy and safety of SGLT2 inhibitors in elderly patients is consistent with younger patients;166 however, additional long-term studies are needed. Thus, the risks and benefits of SGLT2 inhibitors should be assessed in older patients on a case-by-case basis given the newness of the drug class 166…”

Section: Options Of Therapy In Elderly Patientsmentioning

confidence: 99%

Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options

Du¹,

Ou²,

Beverly³

et al. 2014

CIA

View full text Add to dashboard Cite

The prevalence of type 2 diabetes mellitus (T2DM) is increasing in the elderly. Because of the unique characteristics of elderly people with T2DM, therapeutic strategy and focus should be tailored to suit this population. This article reviews the guidelines and studies related to older people with T2DM worldwide. A few important themes are generalized: 1) the functional and cognitive status is critical for older people with T2DM considering their life expectancy compared to younger counterparts; 2) both severe hypoglycemia and persistent hyperglycemia are deleterious to older adults with T2DM, and both conditions should be avoided when determining therapeutic goals; 3) recently developed guidelines emphasize the avoidance of hypoglycemic episodes in older people, even in the absence of symptoms. In addition, we raise the concern of glycemic variability, and discuss the rationale for the selection of current options in managing this patient population.

show abstract

“…However, data extraction from 15 clinical trials showed that in elderly T2DM patients, the A 1c reduction was lower with canagliflozin when compared to younger population, while the reduction in SBP and weight was the same 58. In multiple Phase III studies, there was a significant increase in β-cell glucose sensitivity compared to placebo with canagliflozin, and it was noninferior to sitagliptin.…”

Section: Canagliflozin: Role Of Clinical Profiling – Efficacy and Advmentioning

confidence: 99%

Patient profiling in diabetes and role of canagliflozin

Amblee

2014

PGPM

View full text Add to dashboard Cite

Genome-wide association studies have opened the door for patient profiling and research into genetic variants in multifactorial T2DM. Clinically, it may be possible to tailor the type of medication used based on the presence or absence of the various genetic variants. However, the polymorphisms studied may only explain some of the variability in response to T2DM drugs and needs further validation to ensure its authenticity. There are still unidentified factors which appear to play a role in the interindividual variability seen in clinical practice. The potential exists for pharmacogenomics to promote efficacious, safe, and cost-effective individualized diabetes management. Pharmacogenomics is still in its early stages, and the idea of defining patients genetically to predict individual responses to drugs and obtain safe and effective T2DM management is promising, in spite of existing barriers. Currently, clinical profiling of patients with T2DM and using an individualized approach with most drugs, including canagliflozin, based on comorbid conditions still remains the most accepted approach for the management of T2DM.

show abstract

A Review of the Efficacy and Safety of Canagliflozin in Elderly Patients with Type 2 Diabetes

Cited by 31 publications

References 6 publications

Efficacy and safety of canagliflozin in patients with type 2 diabetes

Efficacy and safety of canagliflozin in patients with type 2 diabetes

Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options

Patient profiling in diabetes and role of canagliflozin

Contact Info

Product

Resources

About